{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:14:05Z","timestamp":1767834845861,"version":"3.49.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mastocytosis is a rare, clinically heterogenous clonal hematological neoplasm. Over 95% of patients harbor the driver KIT D816V mutation resulting in mast cell (MC) accumulation and proliferation in various organs, leading to variable symptom manifestations that result from MC mediator release in patients with systemic mastocytosis (SM) and end-organ damage in those with advanced SM. The accurate diagnostic and clinical classification of patients with SM is vital to underpin appropriate treatment options and personalize therapy. This review evaluates the current diagnostic criteria, clinical classification, risk stratification, and therapeutic options available for adult patients with nonadvanced and advanced SM.<\/jats:p>","DOI":"10.1182\/hematology.2023000505","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:11:11Z","timestamp":1702048271000},"page":"396-406","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Mastocytosis demystified"],"prefix":"10.1182","volume":"2023","author":[{"given":"Scott","family":"Veitch","sequence":"first","affiliation":[{"name":"Haematology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[{"name":"Haematology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"11","key":"2023120815065019700_hem2023000505C1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023120815065019700_hem2023000505C2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"2023120815065019700_hem2023000505C3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"2023120815065019700_hem2023000505C4","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cncr.34420","article-title":"Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: results of the TouchStone SM Patient Survey","volume":"128","author":"Mesa","year":"2022","journal-title":"Cancer"},{"issue":"11","key":"2023120815065019700_hem2023000505C5","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"HemaSphere"},{"issue":"23","key":"2023120815065019700_hem2023000505C6","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2023120815065019700_hem2023000505C7","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"issue":"14","key":"2023120815065019700_hem2023000505C8","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2023120815065019700_hem2023000505C9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2023120815065019700_hem2023000505C10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3324\/haematol.2017.163964","article-title":"The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm","volume":"102","author":"Jawhar","year":"2017","journal-title":"Haematologica"},{"issue":"21","key":"2023120815065019700_hem2023000505C11","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","article-title":"Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models","volume":"2","author":"Pardanani","year":"2018","journal-title":"Blood Adv"},{"issue":"31","key":"2023120815065019700_hem2023000505C12","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: mutation-adjusted risk score for advanced systemic mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023120815065019700_hem2023000505C13","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(20)30400-2","article-title":"Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study","volume":"8","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"2023120815065019700_hem2023000505C14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"\u00c1lvarez-Twose","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"2023120815065019700_hem2023000505C15","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.jaip.2022.03.007","article-title":"Personalized management strategies in mast cell disorders: ECNM-AIM user's guide for daily clinical practice","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"2023120815065019700_hem2023000505C16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"issue":"12","key":"2023120815065019700_hem2023000505C17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: current concepts in diagnosis and treatment","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann Hematol"},{"issue":"4","key":"2023120815065019700_hem2023000505C18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"2023120815065019700_hem2023000505C19","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0091-6749(89)90097-3","article-title":"A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis","volume":"83","author":"Kettelhut","year":"1989","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2023120815065019700_hem2023000505C20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromlyn sodium in the management of systolic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2023120815065019700_hem2023000505C21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"issue":"3-4","key":"2023120815065019700_hem2023000505C22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of aspirin administration in systemic mastocytosis","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"1","key":"2023120815065019700_hem2023000505C23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaci.2007.10.014","article-title":"Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and hymenoptera allergy","volume":"121","author":"Bonadonna","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2023120815065019700_hem2023000505C24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaip.2013.06.014","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations","volume":"1","author":"Bonadonna","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"2023120815065019700_hem2023000505C25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"issue":"6","key":"2023120815065019700_hem2023000505C26","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: a systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"2023120815065019700_hem2023000505C27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5414\/ALX02196E","article-title":"Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis","volume":"5","author":"G\u00fclsen","year":"2021","journal-title":"Allergol Select"},{"issue":"13","key":"2023120815065019700_hem2023000505C28","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"issue":"8","key":"2023120815065019700_hem2023000505C29","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2023120815065019700_hem2023000505C30","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evidence"},{"issue":"12","key":"2023120815065019700_hem2023000505C31","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J Clin Oncol"},{"issue":"40","key":"2023120815065019700_hem2023000505C32","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2017","journal-title":"Oncotarget"},{"issue":"26","key":"2023120815065019700_hem2023000505C33","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"2023120815065019700_hem2023000505C34","first-page":"321","article-title":"Pooled survival analysis of midostaurin clinical study data (D2201+A2213) in patients with advanced systemic mastocytosis compared with historical controls","volume":"102","author":"Reiter","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"2023120815065019700_hem2023000505C35","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"2023120815065019700_hem2023000505C36","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2023120815065019700_hem2023000505C37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2021-150872","article-title":"Effective control of advanced systemic mastocytosis with avapritinib: mutational analysis from EXPLORER clinical study","volume":"138","author":"Deininger","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2023120815065019700_hem2023000505C38","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","article-title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","volume":"36","author":"Reiter","year":"2022","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2023120815065019700_hem2023000505C39","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2022-156311","article-title":"Preliminary safety and efficacy from Apex, a phase 2 international study of bezuclastinib (CGT9486), a novel, highly selective, potent KIT D816V tyrosine kinase inhibitor, in adults with advanced systemic mastocytosis (AdvSM)","volume":"140","author":"DeAngelo","year":"2022","journal-title":"Blood"},{"issue":"29","key":"2023120815065019700_hem2023000505C40","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"2023120815065019700_hem2023000505C41","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.6004\/jnccn.2018.0088","article-title":"Systemic Mastocytosis, Version2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Gotlib","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2023120815065019700_hem2023000505C42","first-page":"103398","article-title":"Advanced systemic mastocytosis with associated haematological neoplasm: treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant","volume":"71","author":"Sriskandarajah","year":"2023","journal-title":"Curr Res Transl Med"},{"issue":"8","key":"2023120815065019700_hem2023000505C43","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/j.jaip.2022.05.034","article-title":"Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis","volume":"10","author":"Gotlib","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/396\/2175653\/396veitch.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/396\/2175653\/396veitch.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:11:25Z","timestamp":1702048285000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/396\/506403\/Mastocytosis-demystified"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000505","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}